|
|
Blood, 15 February 2007, Vol. 109, No. 4, pp. 1355-1362.
Prepublished online as a Blood First Edition Paper on September 28, 2006; DOI 10.1182/blood-2006-06-030858.
Previous Article | Next Article 
Submitted June 21, 2006
Accepted September 20, 2006
Beyond HLA: the significance of genomic variation for
allogeneic hematopoietic stem cell transplantation
Ann Mullally and Jerome Ritz*
Department of Medical Oncology, Dana-Farber Cancer Institute
* Corresponding author; email: jerome_ritz{at}dfci.harvard.edu.
The last two years have seen much excitement in the field of genetics with the identification of a formerly unappreciated level of "structural variation" within the normal human genome. Genetic structural variants include deletions, duplications and inversions in addition to the recently discovered, copy number variants (CNVs). Single nucleotide polymorphisms (SNPs) are the most extensively evaluated variant within the genome to date. Combining our knowledge from these studies with our rapidly accumulating understanding of structural variants, it is apparent that the extent of genetic dissimilarity between any two individuals is considerable and much greater than that which was previously recognized. Clearly, this more diverse view of the genome has significant implications for allogeneic hematopoietic stem cell transplantation (HSCT), not least in the generation of transplant antigens but also in terms of individual susceptibility to transplant related toxicities. With advances in DNA sequencing technology we now have the capacity to perform genome-wide analysis in a high throughput fashion, permitting a detailed genetic analysis of patient and donor prior to transplantation. Understanding the significance of this additional genetic information and applying it in a clinically meaningful way will be one of the challenges faced by transplant clinicians in the future.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. J. Wu and J. Ritz
Revealing Tumor Immunity after Hematopoietic Stem Cell Transplantation
Clin. Cancer Res.,
July 15, 2009;
15(14):
4515 - 4517.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. M. Cao, L. C. Lazzeroni, S. Tsai, W. W. Pang, A. Kao, N. J. Camp, A. Thomas, and J. A. Shizuru
Identification of a Major Susceptibility Locus for Lethal Graft-versus-Host Disease in MHC-Matched Mice
J. Immunol.,
July 1, 2009;
183(1):
462 - 469.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Ofran and J. Ritz
Targets of Tumor Immunity After Allogeneic Hematopoietic Stem Cell Transplantation
Clin. Cancer Res.,
August 15, 2008;
14(16):
4997 - 4999.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. S. Tykodi, N. Fujii, N. Vigneron, S. M. Lu, J. K. Mito, M. X. Miranda, J. Chou, L. N. Voong, J. A. Thompson, B. M. Sandmaier, et al.
C19orf48 Encodes a Minor Histocompatibility Antigen Recognized by CD8+ Cytotoxic T Cells from Renal Cell Carcinoma Patients
Clin. Cancer Res.,
August 15, 2008;
14(16):
5260 - 5269.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. W. Chien, M. J. Boeckh, J. A. Hansen, and J. G. Clark
Lipopolysaccharide binding protein promoter variants influence the risk for Gram-negative bacteremia and mortality after allogeneic hematopoietic cell transplantation
Blood,
February 15, 2008;
111(4):
2462 - 2469.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|